Ro Gains Preferred NovoCare Access

Novo Nordisk effectively turned branded GLP-1 access into a partner ranking system, and Ro moved up when Hims lost its slot. Once compounding became a legal and reputational risk, the scarce asset was no longer telehealth demand, it was clean manufacturer supply wired into the care flow. Ro already had the lab work, follow ups, and insurance routing needed for longer obesity treatment, so keeping NovoCare access made it look more like infrastructure than a lead gen front end.1 2 3 4

• In April 2025, Novo Nordisk named Hims & Hers, LifeMD, and Ro as the three telehealth platforms with direct NovoCare pharmacy access for self pay Wegovy. On June 23, 2025, Novo ended the Hims relationship and said direct Wegovy access through NovoCare would no longer be available there, leaving Ro and LifeMD as the remaining integrated partners.1 2 5
• That mattered because NovoCare was already a meaningful prescription channel. Novo reported around 10,000 weekly Wegovy prescriptions through NovoCare pharmacy, including telehealth collaborations, plus roughly 17,000 weekly prescriptions in the retail cash channel in H1 2025. Ro did not disclose its slice, but the channel was large enough that staying inside it materially improved supply credibility.3
• Ro’s edge versus lighter weight telehealth peers was not a better video visit, it was the ability to keep a patient in one operating loop. Ro Body added a monthly obesity care subscription, and Ro had built in home phlebotomy, diagnostics, owned pharmacies, and insurance routing, which fits manufacturer goals better than a simple prescription handoff.4 6

The next step is that telehealth obesity care keeps consolidating around a small set of manufacturer approved channels and more operationally dense care models. As branded supply normalizes and price gaps compress, platforms like Ro that can manage titration, labs, renewals, and coverage work in one system are positioned to keep winning the highest value GLP-1 patients.2 3 4 6